MSD’s immuno-oncology drug Keytruda has been approved for early-stage lung cancer, totaling its indication count to 25. With the latest approval, Keytruda became the third treatment, alongside AstraZeneca’s Tagrisso and Roche’s Alecensa, that can be used as neoadjuvant and adjuvant therapy. With major lung cancer treatment now approved for early-stage treatments, this approval enhances preventive measures against metastasis and recurrence.

According to the pharmaceutical industry, on 23rd, Ministry of Food and Drug Safety (MFDS) approved an expanded indication for Keytruda (pembrolizumab), a PD-1 inhibitor class anticancer immunotherapy. Previously, on the 19th, Keytruda had received approval for two i